Sugi Predict

Sugi Predict / Compounds / SCHEMBL4803012

SCHEMBL4803012

SCHEMBL4803012

CON(C)C(=O)c1c(Cn2c(=O)n(C)c3ccccc32)sc2c1c(=O)n(C)c(=O)n2CC(C)C

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ SLC16A1 P53985 20/20 0.67
▸ CYP2C9 P11712 8/20 0.67
▸ CYP3A4 P08684 4/20 0.67
▸ ABCB11 O95342 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4798358 0.90 SLC16A1 (0.63) SLC16A1CYP2C9CYP3A4ABCB11
SCHEMBL4802281 0.88 SLC16A1 (0.64) SLC16A1CYP2C9CYP3A4ABCB11
SCHEMBL4804153 0.87 SLC16A1 (0.56) SLC16A1CYP2C9CYP3A4ABCB11
SCHEMBL5790016 0.87 SLC16A1 (0.66) SLC16A1CYP2C9CYP3A4ABCB11
SCHEMBL5788474 0.87 SLC16A1 (0.51) SLC16A1CYP2C9CYP3A4ABCB11
SCHEMBL4803068 0.86 SLC16A1 (0.56) SLC16A1CYP2C9CYP3A4ABCB11
SCHEMBL4796688 0.85 SLC16A1 (0.62) SLC16A1CYP2C9CYP3A4ABCB11
SCHEMBL4799434 0.85 SLC16A1 (0.72) SLC16A1CYP2C9CYP3A4ABCB11
SCHEMBL4803776 0.85 SLC16A1 (0.61) SLC16A1CYP2C9CYP3A4ABCB11
SCHEMBL4797431 0.85 SLC16A1 (0.61) SLC16A1CYP2C9CYP3A4ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361660-B2 Chemical compounds ASTRAZENECA AB (SE) 2008-04-22 — — US claimed
EP-1412362-B1 THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION ASTRAZENECA AB (SE) 2006-08-02 — — EP claimed
US-20040171623-A1 Chemical compounds ASTRAZENECA AB (SE) 2004-09-02 — — US claimed
US-20080153855-A1 Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents ASTRAZENECA AB, A SWEDEN CORPORATION 2008-06-26 — — US disclosed
US-7361660-B2 Chemical compounds ASTRAZENECA AB (SE) 2008-04-22 — — US disclosed
EP-1412362-B1 THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION ASTRAZENECA AB (SE) 2006-08-02 — — EP disclosed
US-20040171623-A1 Chemical compounds ASTRAZENECA AB (SE) 2004-09-02 — — US disclosed
EP-1412362-A1 CHEMICAL COMPOUNDS Astrazeneca AB (SE) 2004-04-28 — — EP disclosed
WO-2003008422-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-01-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153855-A1 Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents HRH4, HRH2, HRH3 SLC16A1 4716/4885CYP2C9 682/4885CYP3A4 397/4885
US-20040171623-A1 Chemical compounds CBR1, SETDB1, CBR3 SLC16A1 1397/4885CYP2C9 63/4885CYP3A4 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.